ATH 33.3% 0.4¢ alterity therapeutics limited

Ann: Webcast Today - New Data from bioMUSE Natural History Study, page-39

  1. 501 Posts.
    lightbulb Created with Sketch. 49
    I think the new endpoint Just presented itself as a low hanging fruit in this trial - it is too irresistible to ignore. Maybe they suspected volume change was a complex variable, at the beginning, but the trial proved otherwise. A volume change might take this gem to market - who knows?
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.